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ABSTRACT 
Cancer is the second leading cause of death in the United States, with 1.74 million new 
cancer cases diagnosed and 610,000 cancer deaths expected in 2018 alone. Current 
treatments often result in negative systemic effects and ineffective treatment of the tumor. 
Drug delivery vehicles have been developed for more effective local delivery methods, but 
many drug delivery vehicles lack spatial and temporal control. Targeted double emulsions 
are a new class of drug delivery vehicles which present a promising option for a high 
payload and controlled delivery. The purpose of our project was to develop and 
characterize an aptamer-chelated double emulsion that has the ability to actively target 
cancer cells and can be activated with ultrasound. AS1411, a 26-base guanine-rich 
oligonucleotide (GRO), was selected since AS1411 has the ability to target nucleolin 
surface receptors, which are overexpressed in many cancerous cell lines. Perfluorohexane 
forms the shell of the drug delivery vehicle since it is ultrasound-responsive in clinically 
acceptable pressure ranges. Ultrasound applied to double emulsions will cause 
vaporization of the perfluorocarbon shell, allowing transport of the molecular compound 
into the cancer cell with a higher efficiency. If a higher concentration is inside the cell than 
the microenvironment, the transient pores can release the molecular compound from the 
cytoplasm. This was seen in our static condition (p=0.054). A fluidic model is needed since 
static conditions doesn’t accurate depict conditions that will be seen in vivo. The payload 
was released from core of the double emulsion. To help reduce the passive release of the 
payload, different surfactants were testing. FluorN562 showed a slower release profile than 
FluorN561 and Poloxamer 188 at 4 oC, 21 oC, and 37 oC (p<0.05), with 21 oC being the 
optimal temperature for storage of double emulsions (p<0.01). Polydispersed double 
emulsions varied too greatly in size for the double emulsions to be used clinically. To 
address this issue, a microfluidic device was developed for the creation of monodispersed 
double emulsions under 10 microns. Double emulsions, once steady state steady flow was 
reached, were constantly between 1 to 2 µm. Ultrasound-responsive double emulsions 
could a potential significant impact clinically allowing for therapeutic molecular 
compounds to enter the cancer cell more easily through the transient pores, which is a 
distinct advantage to this drug delivery system.  
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I. INTRODUCTION 
 In the United States, cancer is the second leading cause of death with an estimated 
610,000 deaths in 2018. While advances in diagnostics and treatment methods have 
occurred, 5 year survival rate is 67% according to Surveillance, epidemiology, and End 
Results [SEER] program. Advances in treatment methods are necessary to increase 
survival rates in the cancer population. Many treatment options are possible for the 
treatment of cancer, but chemotherapy still remains one of the most commonly used 
options for treatment. Chemotherapy treatment has high systemic toxicity and lacks 
effective local delivery to tumors.[1, 2] Multiple reasons can explain the lack of effective 
local delivery, including lack of specificity and rapid clearance in circulation. 
 To help address these issues, drug delivery vehicles have been developed to 
improve specificity and reduce systemic toxicity of chemotherapy.[3] Antibodies and other 
targeting compounds such as aptamers have been added to drug delivery vehicles to 
improve specificity.[3, 4] However, many drug delivery vehicles still lack in effectiveness 
since the drug delivery vehicles often do not efficiently get the chemotherapy into the 
cancer cell.[5-7] 
 To address this limitation, targeted, ultrasound-responsive double emulsions have 
been synthesized to improve the effectiveness of delivering hydrophilic molecular 
compounds to the cell of interest. [8-10] Historically, double emulsions have been used for 
over a hundred years in food and cosmetics industries, but limited research has been 
conducted for biomedical use.[11] Emulsions consist of two immiscible liquids, in which 
one liquid is dispersed within the other causing a droplet to form. A major limitation of 
double emulsions is that double emulsions tend to coalesce without an effective 
surfactant.[12] However, recent developments in synthesis of new biocompatible 
surfactants has helped improve the stability of double emulsions allowing further research 
to be conducted.[13-15] However, lack of an effective controlled release methodology has 
hindered translation to clinical use. To address this limitation, targeted, ultrasound-
responsive 
formulated double 
emulsions have 
been developed to  
enable spatial and 
temporal control 
over release of 
encapsulated 
compounds.[16] Ultrasound-responsive double emulsions are composed of a liquid 
perfluorohexane middle phase encapsulating an aqueous inner phase, shown in figure 1. 
Perfluorohexane is used as the middle phase to prevent hydrophilic drugs from entering 
the bloodstream and diffusing into any cell type. Perfluorohexane is chemically and 
biologically inert with a low boiling point, which allows it to be vaporized into gas phase 
with ultrasound pulses.  
Ultrasound has been widely used for decades in medical and engineering 
applications, including non-destructive testing of materials. More recently, ultrasound 
applications in therapeutics have been investigated. Studies have demonstrated ultrasound-
enhanced therapeutic delivery to cells in vitro and in vivo.[8, 9, 14]
Figure 1- Schematic of targeted double emulsions. 
This delivery technique generally facilitates transmembrane transport of drug by causing 
oscillatory behavior of double emulsions in response to ultrasound.[17] Ultrasound-based 
therapies have several distinct advantages, which includes being non-invasive, portable, 
and targeted. Ultrasound can induce oscillation, rupture, and collapse of the double 
emulsion droplets, which releases the payload from the core of the emulsion.[17-19] The 
perfluorohexane shell undergoes a phase change during vaporization causing a change 
from liquid to gas.[17] It is theorized, due to anisotropic pressures, that inertial cavitation 
will occur, which can cause transient pores in nearby cell membranes and enable transport 
of therapeutic compounds directly into the cytoplasm of cells (fig. 2). [20-23] 
AS1411 was initially discovered by Dr. Paula Bates and colleagues at the 
University of Alabama-Birmingham. Since being discovered, AS1411 has completed 
clinical trials for treatment of acute myeloid leukemia and metastatic renal cell 
carcinoma.[24, 25] For this project, AS1411 aptamer, a 26-mer oligonucleotide, is bound 
Figure 2- Schematic of inertial cavitation induced by vaporization of double emulsion, 
which causes transient pores in the cell membrane. 
to the surface of the double emulsion droplet in order to target nucleolin. In normal cells, 
nucleolin is a multifunctional protein located predominantly in the nucleolus; however, it 
can also be found in the cytoplasm and as a surface receptor.[26-30] Deregulation occurs 
in tumor cells causing an over-expression of nucleolin surface receptors in many tumor cell 
lines.[27, 29] AS1411 binds to nucleolin with high affinity and is taken into the cell through 
mediator receptor macropinocytosis.[26, 30]  
Prior studies have shown that ultrasound can trigger release of therapeutics from 
double emulsions and AS1411 can specifically target cancer cells. Conjugating AS1411 to 
double emulsions will allow effective targeting of cancer cells that overexpress nucleolin 
surface receptors. Once bound, ultrasound can be applied to induce transient pores, 
allowing molecular therapeutics to enter the cell. Therefore, the objective of this project 
was to combine these findings and assess the effect of using ultrasound to induce drug 
release from AS1411-targeted double emulsions in cancer cells.  
  
 
 
 
 
 
 
 
 
 
II. Targeted Drug Delivery to Cancer Cells in Static Culture Conditions 
 
A. Motivation 
When investigating ultrasound-responsive double emulsions, prior research studies 
have not explored the potential ability to chelate an aptamer to ultrasound-responsive 
double emulsion droplets. This led our team to want to investigate this area further. 
Aptamers have the ability to actively target certain cell types based off their phenotype.[4] 
In our case, we selected an aptamer that has the ability to target nucleolin-expressing cancer 
cells, such as the human triple-negative breast cancer (TNBC) cell line MDA-MB-231, 
which we selected for our experimental testing. Our objective was to evaluate whether 
chelating a tumor-targeting aptamer onto the double emulsion improved uptake of the 
payload in the cells compared to untargeted particles. Secondly, we wanted to see if 
ultrasound improved the delivery of the payload compared to control samples which did 
not receive application of ultrasound. 
 
B. Methods 
 
i.) Generation of Polydisperse Targeted Double Emulsions 
 We placed 375 µL of deprotected AS1411 maleimide solution in a microcentrifuge 
tube. By deprotecting AS1411, it will allow the thiol group to react with the maleimide 
group on polar head of the phospholipid surfactant. The thiol group on AS1411 was 
deprotected with 10mM of (tris)(2-carboxyethyl)phosphine) (TCEP) for 1 hour and 
immediately added to lipid solutions for overnight incubation at 4oC to allow the reaction 
to occur. For untargeted control samples we placed 300 µL of 2% maleimide solution and 
75 µL of PBS in a microcentrifuge. Both solutions were used as the surfactant. AS1411 
has been shown to target nucleolin receptors while the maleimide solution without AS1411 
has no functional tumor-targeting moieties. We agitated the solutions using a micropipette 
to ensure thorough mixing. We then added 375 µL of Poloxamer 188 into both solutions 
and stored them at 4 oC. We placed 400 µL of 100 mg/mL fluorescein sodium salt in 
deionized water and 800 µL of perfluorohexane (PFH) in a 15 mL centrifuge tube. 
Fluorescein sodium salt was selected over chemotherapeutic drugs since it has a higher 
fluorescence level, allowing for better quantitative analysis.  Using a 20 kHz sonicator, we 
set the amplitude to 30% for 30 seconds and sonicated the samples while on an ice bath. 
We removed the surfactants from 4 oC storage and placed the entire contents of each 
solution in separate 2 mL glass vials. We pipetted the fluorescein sodium salt/PFH solution 
up and down multiple times to ensure that the solution was well mixed. We then pipetted 
250 µL into each surfactant solution. A septum cap was crimped onto each glass vial, and 
the solution was amalgamated for 45 seconds. We removed each vial from the amalgamator 
and left it to sit for 20 minutes to allow the double emulsions to settle at the bottom of the 
vial.  
 
ii.) Treatment of TNBC Cells at Physiological Conditions 
Seven different treatments were used on MDA-MB-231 cells. The objective of this 
study was to observe if a dose dependent effect occurred, to determine the effect of a 
targeting aptamer on uptake of molecular compound, and to determine the effect of 
ultrasound on release and delivery of the molecular compound from double emulsions. 
Three different doses were used with AS1411-conjugated double emulsions and untargeted 
double emulsions: low dose (25 µL), medium dose (50 µL), and high dose (100 µL). Each 
dose was added at a 1:20 ratio with PBS before treatment to ensure double emulsions were 
well distributed amongst cells. Treatments were added to a petri dish containing MDA-
MB-231 cells. Following treatment with compound, the petri dishes were placed back in 
the CO2 incubator for 4 hours at 37 °C. Following 4 hours in the incubator, groups were 
treated with ultrasound or no ultrasound based on experimental group specification. 
 
 
 
In groups that were treated with ultrasound, the petri dish was scanned across the 
ultrasound beam to ensure triggered release of molecular compound occurred, shown in 
Figure 3. Ultrasound pulses were delivered with an ultrasound imaging system (2.5 MHz, 
ATL P4-1 probe, Verasonics Vantage 64LE system, 3 MPa peak negative pressure). 
Following ultrasound treatment, cells were washed with PBS. Cells were trypsinized to 
remove cells that were adhered to the bottom of the petri dish. Media was used to neutralize 
the trypsin, and the cells were placed in a vial. Cells were spun down at 1000 rpm for 5 
minutes using a centrifuge. Supernatant was removed and cells were resuspended in 1 mL 
before assessing fluorescein uptake using flow cytometry. All data was normalized to 
AS1411 conjugated low dose treatment. Statistical analysis was performed in Minitab 
Figure 3- schematic of experimental setup for treatment of MDA-MB-231 using 
ultrasound to vaporize double emulsions. 
using a two-way ANOVA. For samples imaged with scanning electron microscopy (SEM), 
cells were immediately fixed (< 1 min) in 2.5% glutaraldehyde after ultrasound treatment. 
iii.) Treatment of TNBC with Ultrasound 
The objective of this study was to determine the effect of ultrasound on release and 
delivery of the molecular compound from double emulsions. Two groups were used for the 
treatment of MDA-MB-231 cells: double emulsions (70µL) vaporized with ultrasound and 
double emulsions (70µL) with no treatment. Once MDA-MB-231 cells were treated with 
double emulsions, the petrie dishes were stored at 21oC for 5 minutes. This allowed all the 
double emulsions to sink to the bottom of the petrie dish, and it was stored at 21oC to reduce 
the amount of passive release of the payload. In the group that was treated with ultrasound, 
the petri dish was scanned across the ultrasound beam to ensure triggered release of 
molecular compound occurred, shown in Figure 3. Ultrasound pulses were delivered with 
an ultrasound imaging system (2.5 MHz, ATL P4-1 probe, Verasonics Vantage 64LE 
system, 3 MPa peak negative pressure). Following ultrasound treatment, cells were washed 
with PBS. Cells were trypsinized to remove cells that were adhered to the bottom of the 
petri dish. Media was used to neutralize the trypsin, and the cells were placed in a vial. 
Cells were spun down at 1000 rpm for 5 minutes using a centrifuge. Supernatant was 
removed and cells were resuspended in 250 µL before assessing fluorescein uptake using 
flow cytometry. All data was normalized to double emulsions where ultrasound was not 
applied. Statistical analysis was performed in Minitab using student T-test. 
 
C. Results and Discussion 
 
Tumor-targeted double emulsions versus non-targeted double emulsions showed 
no statistically significant difference (p=0.628). Previous studies have shown that AS1411 
has the ability to target and induce uptake through micropinocytosis in cancer cells. 
Multiple factors could explain the reasoning for the lack of a statistical difference. The 
most plausible explanation is that double emulsions sink in cell culture due to their higher 
density compared to the 
surrounding media, which 
allows the emulsion droplets 
to contact the cells without 
being dependent on ligand-
receptor binding. For future 
studies, a dynamic flow model 
could be used to prevent 
emulsions from accumulating at the bottom of the container before treating with 
ultrasound.  
Ultrasound treatment also did not show any statistically significant increase 
compared to untreated control groups (p=.054). Additional testing is necessary to 
determine if ultrasound has an effect on uptake. In fact, in this study it appears that 
ultrasound may actually have a detrimental effect on uptake. This may be an artifact of the 
experimental setup in which high passive uptake of molecular compounds occurs. In this 
case, ultrasound treatment 
may be inducing leakage of 
the molecular compounds 
from the cells. The purpose of 
ultrasound treatment was to 
cause a phase change in 
perfluorocarbon allowing the 
release of the compound from 
the double emulsion droplets. 
It was theorized that double 
emulsions proximal to a cell 
will induce a collapse of the perfluorocarbon phase which can potentially facilitate rapid 
transport of payload directly to the cell by causing transient pores in the cell’s membrane. 
This led us to further investigate the induced interaction between the double emulsion and 
cell membrane that may be caused by ultrasound treatment. Our finding, shown in figure 
4, indicates the presence of transient pores in the cell membrane following treatment of 
ultrasound. This confirms that ultrasound could have a potential use as a therapeutic 
delivery method from double emulsions. In this circumstance, however, double emulsions 
Figure 4- Image above shows MDA-MB-231 prior to 
treatment with ultrasound-responsive double emulsion 
and image below shows post treatment with ultrasound-
responsive double emulsions. 
Hole in 
membrane 
had the ability to interact with the cancer cells for approximately four hours. This is ample 
time for endocytosis-mediated uptake by the cell. Thus, a high concentration of payload is 
already inside the cell. When vaporization occurs, the payload can actually leave the cell 
by the newly formed transient pores. 
High dose treatment was shown to be statistically different compared to low dose 
(p<.01) and medium dose (p<.01). No statistical difference was found between low dose 
and medium dose (p=0.074), although there was a trend toward significance and a larger 
sample size may have revealed a statistical difference (fig. 5). 
  
 
The results of this study indicated that the double emulsions were not stable after 4 
hours of incubation at 37 °C and spontaneously released their payload prior to ultrasound 
treatment. In addition, molecular compound (i.e. fluorescein) was taken up by cells even 
without AS1411 targeting, indicating non-specific delivery (likely by endocytosis) in the 
static culture system. The SEM image showing pores in the membrane is a positive finding 
since this indicates that molecular compounds could enter the cytosol of the cancer cell 
more easily. Nevertheless, due to limitations of the static cell culture system and double 
emulsion stability we did not observe any significant differences in uptake of the molecular 
compound by cells between experimental groups.  
Figure 5- Shows the relative fluorescence normalized to AS1411 low dose 
treatment. Low, medium, and high dose were all treated with ultrasound, 
excluding the no ultrasound (high dose) group.  
Following the results, surfactants were investigated to determine the ability for it to 
stabilize the particle to reduce the passive release of the payload, which is discussed in 
further detail in the next section. A study 
was performed to further analyze the effect 
that ultrasound had on uptake of the 
payload. Due to the density of the double 
emulsion, we observed that double 
emulsions sank to the bottom of the 
container within the first minute (fig. 6). A 
group was treated with ultrasound after 5 
minutes and was compared to a group that 
was not treated with ultrasound to determine 
if ultrasound had an impact on uptake of molecular compound. It was determined that 
ultrasound treatment induced more uptake of fluorescein (p<0.05) (fig. 7). 
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Figure 6- Image taken 1 minute after placing 
double emulsions in culture. 
Figure 7- compares the effect of ultrasound on fluorescein uptake. All data 
was normalized to no ultrasound treatment. 
Double 
Emulsions 
 III. Characterization of Surfactant Effects on Double Emulsion Stability 
 
A. Motivation 
Based off of the synthesis techniques described above, double emulsions could not 
be stored long term for usage. Double emulsions had to be synthesized and used for 
experiments right away. In the next experimental study, different surfactant types, 
concentrations, and temperatures were tested to see the effect on the release profile of the 
double emulsions and increase the storage shelf-life of double emulsions. For double 
emulsions to be translated to the clinic, they must be able to be synthesized and stored for 
a duration of time prior to treatment without releasing the payload. With a more stable 
surfactant, a slower release profile will take place. Also, the effect of temperature on double 
emulsion stability was investigated to determine leakage of the internal payload over time 
at different temperatures. 
 
B. Methods 
 
i.) Synthesis of Double Emulsions 
We evaluated three different surfactants for experimental testing: Poloxamer 188 
(Sigma-Aldrich), FluorN561 (Cytonix), and FluorN562 (Cytonix). Poloxamer 188 is a 
nonionic copolymer composed of a hydrophobic chain flanked by two hydrophilic chains. 
Poloxamer 188 has been commonly used as a surfactant for research due to its 
biocompatibility. However, for double emulsion use, it was unclear if it would provide 
enough stability for drug delivery applications. Thus, other surfactants were investigated. 
FluorN561 and FluorN562 are non-ionic, ethylene glycol-based fluorosurfactants and have 
the same structural backbone (fig. 8). Fluor561, commonly denoted as N561, contains one 
perfluro group and three polyethylene glycol groups, and FluorN562, commonly denoted 
as N562, contains two perfluoro groups and two polyethylene glycol groups. Both of these 
surfactants appeared advantageous since both are expected to be biocompatible and had 
longer chains compared to Poloxamer 188. The longer chain lengths may reduce 
coalescence of the drug delivery vehicles.  
 
 
Figure 8- shows the structural backbone of FluorN561 and FluorN562. Functional groups, 
which are either hydrophobic or hydrophilic in nature, are attached to the A and * 
terminals. 
We diluted each solution to three different concentrations for testing. Poloxamer 188 
concentrations were tested at 1%, 2.5%, and 5% (w/v). N561 and N562 concentrations 
were tested at 0.2%, 0.5%, and 1% (w/v). Stock solutions were prepared at 10% (w/v) for 
Poloxamer 188 and 2% (w/v) for FluorN561 and FluorN562. For the lowest concentration 
of each solution, 200 µL was added to 1.8 mL of PBS. For the middle concentration, 500 
µL was added to 1.5 mL of PBS. For the highest concentration, 1 mL was added to 1 mL 
of PBS. In a 2 mL glass vial, 200 µL of fluorescein deionized water solution at a 
concentration of 200 mg/mL was added to 1.5 mL of diluted surfactant. A septum cap was 
crimped onto the glass vial and the solution was amalgamated for 45 seconds. Following 
amalgamation the solution was left undisturbed on the bench for 20 minutes at room 
temperature. This allowed the double emulsions to settle on the bottom of the solution.  
 
ii.) Washing Procedure for Double Emulsions 
Double emulsion washing steps were included to remove unencapsulated 
compounds from the solution. Prior to removing the supernatant that contained the free 
compounds, additional solutions were made for washing the emulsions. Resuspension in 
PBS is a common methodology for most methods; however, it was discovered that in a 
PBS solution without surfactants, the double emulsion would release its compound very 
quickly. To prevent that from occurring, we prepared 5 mL solutions of 1%, 2.5%, and 5% 
Poloxamer 188, 5 mL solutions of 0.2%, 0.5%, and 1% FluorN561, and 5 mL solutions of 
0.2%, 0.5%, and 1% FluorN562 using PBS. We removed 1 mL aliquots of each surfactant 
concentration and pipetted it into a separate vial. We then removed double emulsions of 
each solution and gently pipetted them into corresponding vials that contained 1 mL of 
surfactant. We allowed 5 minutes for the double emulsions to settle, then we remove the 
supernatant from the solution. We carefully washed an additional three times and removed 
the supernatant, allowing double emulsions to settle for 3 minutes each time.  
 
iii.) Release Profile of Double Emulsion 
For each surfactant type and concentration, three samples were prepared. Each 
sample was covered with foil to prevent photobleaching of the fluorescence in the solution. 
For N562 and Poloxamer 188 samples, the three concentrations were stored at three 
different temperatures to observe the effect that temperature has on the release profile for 
each emulsion type. N561 was not sampled since stable formation of double emulsions did 
not occur with this surfactant. The conditions were 4 oC, 21 oC, and 37 oC. 20 µL aliquots 
were taken from the supernatant of each sample and placed in a 96 well plate. We then 
added 180 µL of deionized water to dilute each sample in the 96 well plate. Fluorescence 
was measured with a spectrofluorometer using an excitation wavelength of 488 nm and an 
emission wavelength of 520 nm. The measurements were acquired at 1 hr, 2 hr, 4 hr, 24 
hr, 72 hr, and 72hr post treatment. All data was normalized to the last data point taken.  
 
 
 
 
 
 
 
C. Results and Discussion 
 
Figure 9- shows the release profile for Poloxamer 188 and N562 at different 
surfactant concentrations up and being stored at 4oC. All data was normalized 
to 72 hour post-treatment with ultrasound. 
  
 
 
Figure 10-shows the release profile for Poloxamer 188 and N562 at different 
surfactant concentrations up and being stored at 21oC. All data was normalized 
to 72 hour post-treatment with ultrasound. 
  
 Initial testing showed that temperature may have a significant effect on the passive 
release profile of the emulsion droplets but was not statistically significant. Passive release 
profile occurs when the payload crosses the perfluorohexane shell into solution prior to the 
vaporization of the double emulsions. For Poloxamer 188 and N562 emulsions at 37 oC 
(fig. 11), almost all of the fluorescein was released from the double emulsions within 1 
hour. This suggests that an additional surfactant is necessary to have a more sustained 
release profile at that temperature. For Poloxamer 188 and FluorN562 emulsions at 4 oC 
and 21 oC (fig. 9 & 10), a slower release profile occurred. This suggests that either 4 oC or 
21 oC may be used for emulsion storage before treatment. FluorN561 is not a viable option 
Figure 11- shows the release profile for Poloxamer 188 and N562 at different 
surfactant concentrations up and being stored at 37oC. All data was normalized to 72 
hour post-treatment with ultrasound. 
 
as a surfactant for double emulsions due to the inability for stable double emulsions to be 
formed.  
 Additional testing was performed to further examine the effect that surfactant and 
temperature has on release profile of double emulsions. FluorN562 performed better than 
Poloxamer188 at each temperature (p<0.05). FluorN562 showed a slower release profile 
(fig. 12).  In order for ultrasound-responsive, targeted double emulsions to be used 
clinically, a slow release profile is needed so that the emulsion remains intact until it is 
vaporized by ultrasound at the target site. This will allow a potentially high amount of 
payload to be delivered to the tumor.  FluorN562 at 21oC exhibited the best release profile 
(p<0.05). Although 21oC appeared to be optimal, it is important to consider that cooling 
and heating of perfluorohexane from 21oC may have had an impactful role on the release 
profile. It was observed as time progressed, the surfactant and solution and would separate, 
potentially altering the release profile of double emulsions. 
Figure 12- Shows the relative fluorescence for each surfactant and corresponding 
temperature. Each data set was normalized to their last measured point at 72 
hours. 
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 To improve double emulsion stability, multiple parameters should be considered. 
Double emulsions tend to coalesce without a surfactant. To prevent coalescing from 
occurring, surfactants are used. Surfactant type and chain length are both important 
properties to consider. When selecting a surfactant, non-ionic surfactant appear to be 
suitable since it contains no charge and contains polar head groups, which prevents 
interaction between groups. Chain length is also critical. By increasing chain length, 
interaction between the perfluorohexane shell should be reduced, reducing the amount of 
double emulsions that coalesce.  
 
 
 
 
 
IV. Microfluidic Synthesis of Monodisperse Double Emulsions 
 
A. Motivation 
Perfluorocarbon-based double emulsions could have a profound effect clinically 
for targeted delivery of therapeutic compounds. However, prior limitations have included 
inadequate droplet size and heterogeneity of double emulsion suspensions. In order for 
double emulsions to be used clinically, the emulsion droplets must be smaller than 5 
microns to travel through the capillaries. Microfluidic devices were developed to 
synthesize monodispersed double emulsions that are under 5 microns. Monodisperse 
double emulsions have many advantages compared with polydisperse double emulsions. 
With monodisperse double emulsions, the size of each droplet in the emulsions is known 
and can be reproduced consistently, thus it is possible to perform quality control to 
determine if the emulsions could be used clinically based on the size, but with polydisperse 
double emulsions there can be a large variance in size and the distribution can vary between 
batches.  
 
B. Design 
Multiple components were considered in the design of the microfluidic system, 
which included flow type and channel size. Flow characteristics have an important impact 
on output of double emulsions. If flow is turbulent, steady production of double emulsions 
will not occur since coalescence of droplets is more likely to occur. Channel size is an 
important factor in double emulsion production. If channels are too small, clogging is likely 
to occur. We modified a special design recently described in the literature (fig. 13),[31] 
which employs a double-layer format to enable formation of very small double emulsions 
(less than 10 microns in diameter) through an orifice. 
 
 
C. Methods 
 
Figure 13- Schematic of 
microfluidic device used to create 
monodispersed double emulsions. 
i.) Fabrication of Microfluidic Devices 
The SU8 master was fabricated on a silicon wafer at the UofL Micro/Nano 
Technology Center using standard photolithography techniques. PDMS-based microfluidic 
devices were fabricated using previously established methods. Briefly, 60 g of silicone base 
and 6 g of curing agent was added to a cup and was mixed thoroughly using a stir stick. 
The cup containing the mixture was degassed by placing it in the desiccator until air 
bubbles were no longer visible. All of the PDMS was poured over the SU8 master and 
placed back into the desiccator to remove any remaining air bubbles. Following the 
removal of all bubbles, the device was baked for 2 hours at 60 oC in a lab oven. The PDMS 
was carefully peeled off the SU8 master before removing PDMS devices. Each individual 
device was cut from the PDMS block using a razor blade. The microfluidic inlets and 
outlets were punched in the PDMS using a 2 mm biopsy puncher. Once devices were 
prepared, they were treated with oxygen plasma (100 V for 60 s, 0.5 atm of O2) and 
immediately bonded onto glass microscope slides.   
 
ii.) System Preparation 
The microfluidic device was placed on the stage of an inverted microscope coupled 
with a digital camera that can take frames less than 100 µs apart. Syringes were mounted 
on a syringe pump for continuous infusion into the microfluidic device. We found that 
syringes of 10 mL or larger were optimal. Syringe were primed before attaching 
approximately 45 cm lengths of flexible tygon PVC tubing (1/16” ID, 1/8” OD) to the 
syringes. We connected the loose ends into the appropriate input ports in the device. We 
also inserted a 15 cm length of the tygon PVC tubing into the output port. We primed the 
device by running the syringe pump at high rates of speed (4 mL/min) until fluid in the 
tubing reaches the inlet channels of the device. 
 
iii.) Generation of Monodisperse Double Emulsions 
We focused the microscope on a region of the device where the 10 µm wide channel 
converged with the 50 µm channel and contained the 50 µm by 50 µm orifice. We set the 
syringe pumps to 500 µl/hr for the inner phase and 500 µL/hr for the middle phase. We 
allowed continuous flow for 5 minutes to reach steady state. We ran the syringe pump at 
2000 µL/hr for the continuous (outer) phase, also allowing 5 minutes to reach steady state. 
We maintained flow rates of the inner and middle phase and incrementally increased the 
flow at 200 µL/hr each minute for the continuous phase until 5,000 µL/hr was reached. We 
allowed steady state to be reached for the continuous double emulsion generation and then 
acquired videos and images as double emulsions were generated in the device.   
 
iv.) Emulsion imaging 
We pipetted 50 µL of solution from the bottom of the collecting vial, then placed 
the solution in 1 mL of phosphate-buffered saline (PBS). We ensured that the solution was 
well-mixed, then pipetted 5 µL of PBS solution mixture onto a microscope slide for 
imaging under a fluorescent microscope. We adjusted the optical filter to the appropriate 
setting to ensure detection of the double emulsion encapsulated payload. We placed a scale 
bar on the image to determine droplet size. ImageJ was used to analyze the diameter of the 
double emulsion. 
 
D. Results and Discussion 
 PDMS microfluidic 
devices are capable of generating 
water/oil/water (w/o/w) double 
emulsions using coaxial flow. In 
order to have laminar flow, it is 
essential that the channels are 
aligned properly. When the 
channels were properly aligned 
and no clogging of the channels 
occurred, double emulsions were able to be generated as small as 1 µm and ranged from 1 
µm to 2 µm in size (fig. 14).  
We found that the current 
design state of the microfluidic 
device has many limitations. The 
system is very sensitive to changes 
in pressure and takes a significant 
amount of time to reach steady 
state (fig. 15). An introduction of 
an air bubble to the system will 
cause the device to stop producing double emulsions for a period of time due to the 
variability in pressure. Another limitation is the amount of time that it takes for the 
microfluidic device to create enough double emulsions for treatment. It is estimated that a 
Figure 14- shows the size of double emulsions (scale 
bar= 100 µm) and monodispersity of double 
emulsions. 
Figure 15- shows the generation of double emulsions 
in the orifice at steady state. 
typical clinical dose requires about 1 billion double emulsions. With the current flow rate, 
it takes approximately 19 hours just to produce a single dose.  
Changes in design can potentially address these issues. A pressure regulator can be 
added to maintain steady pressure, allowing a constant production of double emulsions. 
Designing a new microfluidic system with multiple outputs can increase the droplet 
production rate significantly. Both of these design changes could address the current 
limitations compared to other synthesis methodologies.   
 
 
 
 
 
V. Conclusions  
 Static testing of double emulsions is an ineffective method to determine the 
potential effect that double emulsions may have clinically since this setup does not replicate 
human physiological conditions. With the current experimental methodology, double 
emulsions interact with the cells of interest for much longer than they would under 
physiological conditions. With static culture, it is difficult to test the potential use of a 
targeting moiety since double emulsions have a higher density than the cell culture 
solution, allowing them to sink and interact with the cells of interest even without a 
targeting moiety. With current protocols for treatment of cancer cells in static conditions, 
ultrasound could appear to have a negative effect on delivery of molecular compounds. 
Since ultrasound treatment can cause transient pores in the cell membranes, this can allow 
molecular compounds in the cell cytosol to leak outwards after passive uptake occurs. 
However, the fact that ultrasound can induce transient pores with double emulsions can 
still be viewed as a positive factor, since dynamic conditions will occur in the body which 
may prevent passive uptake of double emulsions by cancer cells. Thus, it is critical to have 
an ability to deliver the payload with spatial and temporal control. 
 Surfactants play a fundamental role in the stabilization and release profile of double 
emulsions. For storage and clinical applications it is fundamental that the double emulsion 
has a surfactant that is biocompatible and causes the emulsion to have a slow passive 
release profile. Most research pertaining to the formulation of ultrasound-responsive 
double emulsions has used Poloxamer 188. However we have exhibited the importance of 
testing other surfactants due to the release profile associated with Poloxamer 188. Double 
emulsions with N562 as the surfactant showed a slower release profile than Poloxamer 
188.  
 Development of a reliable microfluidic device design is fundamental for the project 
moving forward. With the current design, double emulsions can be generated as small as 1 
µm in size. This would allow the emulsions to travel through the capillaries if used 
clinically. The microfluidic device design is currently limited by slow and inconsistent 
production of double emulsions. To address both of these limitations, multiple inlet and 
multiple outlets can be incorporated into the design and the flow can be regulated by 
pressure instead of flow rate.  
 If successful, tumor-targeted double emulsions that are ultrasound-responsive 
could have a significant clinical impact. The drug delivery system has the ability to target 
the cells of interest and can use many different types of aptamers and antibodies. Along 
with that, the drug delivery system has the ability to carry many different molecular 
compounds, not just chemotherapy. Development of drug delivery systems that are 
environmentally sensitive have gained much interest since cancer cells differ in their 
localized environment, such as temperature and pH. These technologies lack in the ability 
to cause transient pores in the cell membrane allowing for effective delivery of molecular 
compound to the cytosol. Therefore, ultrasound-responsive formulations could lead to 
more effective delivery of therapeutic molecular compounds for treatment of cancer cells. 
 
 
 
 
VI. Future Work 
 Being at the initial stages of development for a platform technology, a significant 
amount of issues have to be addressed in order for the project to progress forward. If these 
recommendations are met in the future, we believe that this could have a potential 
significant impact clinically. Below are a few topics that need to be addressed or require 
further investigation. 
 For this project to advance forward, synthesis of double emulsions should be 
performed by a microfluidic device. Microfluidics is currently hampered by its inability to 
create ample amounts of double emulsions in short period of time, and the inability for the 
device to maintain a constant pressure for long periods of time. To address the need to 
create double emulsions in a short period of time, a new design should be created that 
combines multiple parallel devices into one system to increase production rates. To address 
the issue for maintaining constant pressure in the device, the system input pressure should 
be carefully regulated instead of maintaining a constant flow rate. This will prevent small 
air bubbles in the system from having a significant impact on double emulsion droplet 
production.  
 Further testing of surfactants should occur to test the effect that each surfactant has 
on the stability of the particle. The double emulsions may have to circulate throughout the 
body for multiple days depending on the conjugated targeting group. In order for it to be 
used clinically, it must be able to withstand 37 oC without passively releasing a significant 
amount of the compound.  
 Finally, an experimental flow model should be implemented and tested. With static 
culture experiments, many limitations exist and this setup does not give an accurate 
representation of the potential impact that a targeting moiety and ultrasound can have on 
delivery of molecular compounds in a clinical setting. Once the implementation of a flow 
model occurs, the testing protocol should be extensively considered to ensure it replicates 
similar conditions that may be seen in vivo and the model may clearly show the effect that 
a targeting group and ultrasound can have on delivery of molecular compounds to cancer 
cells.  
Current chemotherapy delivery techniques have many limitations making drug 
delivery devices an area of interest. If successful results are seen, ultrasound-activated 
double emulsions for targeted therapy could have significant impact by reducing negative 
systemic effects and increasing uptake by cancer cells, including dormant cancer cells. 
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